Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APM NASDAQ:FBLG NASDAQ:INM NASDAQ:ONCO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPMAptorum Group$0.80$0.88$0.65▼$4.47$5.09M0.38313,236 shs20,387 shsFBLGFibroBiologics$0.88$1.04$0.73▼$14.68$4.56M1.14196,700 shs58,859 shsINMInMed Pharmaceuticals$1.56$1.27$0.58▼$3.28$5.17M0.9552,715 shs33,099 shsONCOOnconetix$0.96$2.61$0.88▼$270.00$1.09M2.69716,843 shs388,192 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPMAptorum Group+0.25%+3.28%-17.83%-13.33%-13.20%FBLGFibroBiologics-3.40%+19.41%-16.62%-36.56%-92.83%INMInMed Pharmaceuticals-1.89%+3.31%+2.63%+130.09%-48.85%ONCOOnconetix-11.53%-2.48%-16.18%-93.71%-99.61%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPMAptorum Group$0.80$0.88$0.65▼$4.47$5.09M0.38313,236 shs20,387 shsFBLGFibroBiologics$0.88$1.04$0.73▼$14.68$4.56M1.14196,700 shs58,859 shsINMInMed Pharmaceuticals$1.56$1.27$0.58▼$3.28$5.17M0.9552,715 shs33,099 shsONCOOnconetix$0.96$2.61$0.88▼$270.00$1.09M2.69716,843 shs388,192 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPMAptorum Group+0.25%+3.28%-17.83%-13.33%-13.20%FBLGFibroBiologics-3.40%+19.41%-16.62%-36.56%-92.83%INMInMed Pharmaceuticals-1.89%+3.31%+2.63%+130.09%-48.85%ONCOOnconetix-11.53%-2.48%-16.18%-93.71%-99.61%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPMAptorum Group 1.00SellN/AN/AFBLGFibroBiologics 2.00Hold$74.008,352.31% UpsideINMInMed Pharmaceuticals 1.00SellN/AN/AONCOOnconetix 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest ONCO, INM, APM, and FBLG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/29/2026APMAptorum Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/29/2026ONCOOnconetix Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)6/24/2026INMInMed Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/17/2026FBLGFibroBiologics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)6/11/2026ONCOOnconetix Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)6/4/2026APMAptorum Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/1/2026FBLGFibroBiologics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)5/29/2026ONCOOnconetix Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)5/20/2026APMAptorum Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/8/2026ONCOOnconetix Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)5/6/2026APMAptorum Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)(Data available from 7/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPMAptorum GroupN/AN/AN/AN/A$2.17 per shareN/AFBLGFibroBiologicsN/AN/AN/AN/A$1.85 per shareN/AINMInMed Pharmaceuticals$4.94M1.05N/AN/A$6.71 per share0.23ONCOOnconetix$810K1.34N/AN/A$505.29 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPMAptorum Group-$1.36MN/AN/AN/AN/AN/AN/AN/AN/AFBLGFibroBiologics-$18.65M-$6.93N/AN/AN/AN/A-767.07%-195.56%7/30/2026 (Estimated)INMInMed Pharmaceuticals-$8.16M-$2.89N/AN/AN/A-132.87%-80.85%-68.11%9/18/2026 (Estimated)ONCOOnconetix-$14.03M$11.400.08N/AN/A-1,316.28%-101.08%-47.34%8/17/2026 (Estimated)Latest ONCO, INM, APM, and FBLG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/30/2026Q2 2026FBLGFibroBiologics-$0.8250N/AN/AN/AN/AN/A5/6/2026Q3 2026INMInMed Pharmaceuticals-$94.4436-$0.69+$93.7536-$0.73$1.20 millionN/A4/30/2026Q1 2026FBLGFibroBiologics-$1.3340-$1.33+$0.0040-$1.33N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAPMAptorum GroupN/AN/AN/AN/AN/AFBLGFibroBiologicsN/AN/AN/AN/AN/AINMInMed PharmaceuticalsN/AN/AN/AN/AN/AONCOOnconetixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPMAptorum GroupN/A0.780.78FBLGFibroBiologicsN/A1.591.59INMInMed PharmaceuticalsN/A3.123.12ONCOOnconetixN/A1.411.37Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPMAptorum Group3.80%FBLGFibroBiologicsN/AINMInMed Pharmaceuticals20.12%ONCOOnconetix23.89%Insider OwnershipCompanyInsider OwnershipAPMAptorum Group63.99%FBLGFibroBiologics9.30%INMInMed Pharmaceuticals0.85%ONCOOnconetix0.27%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPMAptorum Group306.35 million2.29 millionNot OptionableFBLGFibroBiologics105.21 million4.73 millionN/AINMInMed Pharmaceuticals103.31 million3.29 millionNot OptionableONCOOnconetix121.14 million1.14 millionN/AONCO, INM, APM, and FBLG HeadlinesRecent News About These CompaniesOnconetix (NASDAQ:ONCO) Trading Down 6.5% - Here's WhyJune 25, 2026 | americanbankingnews.comOnconetix Highlights Realbotix’s Launch of Humanoid Robot and AI Teachers Assistant Pilot Program in New York State School DistrictJune 24, 2026 | markets.businessinsider.comOnconetix Announces Realbotix Optio and M-Series Humanoid Robot Pilot at Salamanca City Central School DistrictJune 24, 2026 | quiverquant.comQOnconetix Highlights Realbotix's Launch of Humanoid Robot and AI Teachers Assistant Pilot Program in New York State School DistrictJune 24, 2026 | globenewswire.comOnco-Innovations Engages Nanosoft Polymers to Advance Polymer and Drug Delivery Development for ONC010June 23, 2026 | accessnewswire.comAOnco-Innovations Announces Non-Brokered LIFE OfferingJune 19, 2026 | accessnewswire.comAOnco-Innovations Reports Completion of 300g Active Pharmaceutical Ingredient for ONC010 Scale-Up Supporting IND-Enabling DevelopmentJune 19, 2026 | accessnewswire.comAOnco-Innovations Completes Project with Kuano, Using Their Quantum-Based Platform to Deliver Insights for PNKP Inhibitor Technology OptimizationJune 16, 2026 | accessnewswire.comAOnconetix, Inc. Announces 1-for-10 Reverse Stock SplitMay 19, 2026 | globenewswire.comRealbotix Provides Update on Nasdaq ListingMay 19, 2026 | businesswire.comOnconetix Inc. Reports New Clinical Data Supporting Proclarix® in Reducing Overdiagnosis and Launches PRIME Study with LabcorpMay 13, 2026 | quiverquant.comQOnconetix Reports Q1 2026 Progress at Proteomedix AG, Including Two New Peer-Reviewed Publications and Initiation of U.S. Validation StudyMay 13, 2026 | globenewswire.comOnconetix Shareholders Approve Flexible Reverse Stock Split AuthorizationMay 8, 2026 | theglobeandmail.comOnconetix Reshapes Board Leadership With New Chairman, DirectorApril 24, 2026 | tipranks.comOnconetix: HRT financial, 10% owner, sells $110,169 in stockApril 23, 2026 | investing.comInsider Selling: Onconetix (NASDAQ:ONCO) Major Shareholder Sells 49,710 Shares of StockApril 23, 2026 | insidertrades.comOnconetix (NASDAQ:ONCO) Major Shareholder Acquires $25,284.28 in StockApril 22, 2026 | insidertrades.comOnconetix (NASDAQ:ONCO) Major Shareholder Financial Lp Hrt Buys 74,350 SharesApril 17, 2026 | insidertrades.comOnconetix, Inc. Common Stock (ONCO)April 10, 2026 | nasdaq.com(PMZN) Onconetix Highlights Realbotix's Launch of Vinci AI Vision System with Delivery of First Vinci-Equipped Humanoid Robot to EricssonApril 10, 2026 | marketwatch.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesCheap Thrills: Why These 3 Entertainment Stocks Are SoaringBy Dan Schmidt | June 17, 2026Flying Under the Radar: Lockheed Martin's $2.8B Stealth SetupBy Jeffrey Neal Johnson | June 17, 2026The Netflix-Lionsgate Rumor Exposed a Bigger Shift in Media M&ABy Jeffrey Neal Johnson | June 19, 2026Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 BillionBy Jeffrey Neal Johnson | June 11, 2026Plot Twist: How the $110B Paramount-Warner Deal Rewrites MediaBy Jeffrey Neal Johnson | June 16, 2026ONCO, INM, APM, and FBLG Company DescriptionsAptorum Group NASDAQ:APM$0.80 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$0.81 +0.01 (+1.00%) As of 07/2/2026 06:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.FibroBiologics NASDAQ:FBLG$0.88 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$0.87 0.00 (-0.51%) As of 07/2/2026 07:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.InMed Pharmaceuticals NASDAQ:INM$1.56 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$1.52 -0.04 (-2.24%) As of 07/2/2026 06:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.Onconetix NASDAQ:ONCO$0.96 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$0.97 +0.01 (+1.10%) As of 07/2/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst SanDisk’s Volatility May Be Telling Bulls What They Want to Hear Why the Comcast Spin-Off Won't Fix What's Actually Broken Shorting the Grid: Bloom Energy’s $25B AI Power Play AST SpaceMobile’s Japan Catalyst Puts Its Rollout Story Back in Focus Why Kroger's Giant Eagle Deal Could Change Everything SMRs Spark a Chain Reaction for Nano Nuclear Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
